Reported Friday, Calidi Biotherapeutics' Warrants To Be Delisted By NYSE American Following Low Trading Price
Portfolio Pulse from Benzinga Newsdesk
Calidi Biotherapeutics' warrants are set to be delisted by NYSE American due to low trading prices, though its common stock (CLDI) will continue trading.
October 21, 2024 | 7:49 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Calidi Biotherapeutics' warrants will be delisted by NYSE American due to low trading prices, but its common stock (CLDI) will continue trading.
The delisting of warrants may indicate financial challenges or low investor interest, but since the common stock continues to trade, the immediate impact on CLDI is neutral. Investors may be cautious but not necessarily deterred.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 80